Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05363280 · ClinicalTrials.gov registry record · Phase 2

Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC

A Phase 2 study of Small-cell Lung Cancer, sponsored by Advenchen Pharmaceuticals.

Active
Registry status
Phase 2
Development phase
36
Enrollment target
6
Study locations

NCT05363280 is a Phase 2 study of Small-cell Lung Cancer that is active but no longer recruiting, run by Advenchen Pharmaceuticals. The registered enrollment target is 36 participants, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (84% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05363280, a Phase 2 study of Small-cell Lung Cancer, is active but no longer recruiting, sponsored by Advenchen Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
36 participants
Enrollment target
6
Study locations

Study Summary

This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients who need ≥2nd line treatment .

Conditions Studied

Small-cell Lung Cancer

Interventions

  • DRUG AL8326 low dose group
  • DRUG AL8326 middle dose group
  • DRUG AL8326 high dose group

Study Locations (6)

Other

  • Hospital Universitari Vall d'Hebron - Barcelona
  • Hospital Universitario Ramón Y Cajal - Madrid

Alabama

  • University of Alabama at Birmingham - Birmingham

Illinois

  • Northwestern University - Chicago

Missouri

  • Siteman Cancer Center, Washington University - St Louis

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 36 participants
Start Date 2022-11-01
Est. Completion 2026-12
Phase Phase 2

Sponsor

Advenchen Pharmaceuticals

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05363280

The ClinicalTrials.gov registry entry for NCT05363280 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 232-participant average among 79 other Small-cell Lung Cancer trials with a reported enrollment target (84% lower). The listed sponsor is Advenchen Pharmaceuticals, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Small-cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which AL8326 low dose group is the first listed.

NCT05363280 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Other, Alabama, Illinois.

Frequently Asked Questions

What is clinical trial NCT05363280 about?

NCT05363280 is a clinical study titled "Phase 2 Safety and Efficacy Evaluation of AL8326 in ≥2nd Line SCLC". This trial is a Phase II trial designed to evaluate the safety and efficacy of using oral AL8326 , a multi-targeted receptor Tyrosine Kinase Inhibitor( TKI) , to recurrent, advanced, or metastatic small cell lung cancer (SCLC) patients who need ≥2nd line treatment .

What is the current status of trial NCT05363280?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2022-11-01. Estimated completion is 2026-12.

What conditions does trial NCT05363280 study?

This clinical trial studies the following conditions: Small-cell Lung Cancer.

What interventions are being tested in trial NCT05363280?

The interventions under investigation include: AL8326 low dose group (DRUG), AL8326 middle dose group (DRUG), AL8326 high dose group (DRUG).

Who is sponsoring clinical trial NCT05363280?

This trial is sponsored by Advenchen Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05363280 being conducted?

This trial has 6 study locations across Alabama, Illinois, Missouri, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Small-cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Small-cell Lung Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.